Scholarlink

Introduction <p>Concomitant anti-programmed cell death protein 1 (anti-PD-1) therapy and denosumab treatment can improve clinical outcomes of non-small cell lung cancer (NSCLC) patients with bone metastasis. However, limited data are available among Chinese patients in real-world clinical practice, and the effect of this treatment combination on bone metastases has not been adequately studied.</p> Methods <p>This single-centre, retrospective study analysed NSCLC patients with bone metastases who received first-line anti-PD1-therapy and concomitant denosumab treatment between March 2021 and June 2022. Clinical outcomes were described and bone lesion response was evaluated using a novel, exploratory quantitative method based on single photon emission computed tomography/computed tomography scans.</p> Results <p>Among 66 included patients, the median overall survival was 21.5 months (95% CI: 17.0-NR). The overall survival rate (95% CI) was 96.9% (92.9%–100.0%) at 6 months and 79.7% (70.4%–90.2%) at 12 months. The median progression-free survival was 7.7 months (95% CI: 6.2–12.8). The overall response rate was 36.4% (95% CI: 24.9%-49.1%), with 24 (36.4%) patients having partial response. An exploratory subgroup analysis showed that patients who received ≥ 6 doses of denosumab may have longer median overall survival compared to the &lt; 6 doses subgroup (23.3 vs. 15.3 months, <i>P</i> = 0.023), though immortal time bias and confounding limit interpretation. Out of 33 bone lesions identified, 28 had decreased uptake values between consecutive bone scans (mean change in region-of-interest ratio: -32.7%±19.2%).</p> Conclusion <p>This study described real-world clinical NSCLC patients with bone metastases receiving concomitant anti-PD-1 therapy and denosumab. The findings should be interpreted as exploratory and hypothesis-generating given the retrospective, single-arm design. The novel, quantitative assessment method may provide an exploratory approach to monitoring changes in bone lesions, and further validation in larger, prospective cohorts is required.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical outcomes of concomitant anti-PD-1 therapy and denosumab treatment in non-small cell lung cancer patients with bone metastasis: a single-center retrospective study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月26日

查看全文
  • Mengjiao Fu,
  • Ninghu Liu,
  • Jingjing Qu,
  • Qian Shen,
  • Jing Zheng,
  • Yuekang Li,
  • Jianya Zhou,
  • Jianying Zhou

摘要

Introduction

Concomitant anti-programmed cell death protein 1 (anti-PD-1) therapy and denosumab treatment can improve clinical outcomes of non-small cell lung cancer (NSCLC) patients with bone metastasis. However, limited data are available among Chinese patients in real-world clinical practice, and the effect of this treatment combination on bone metastases has not been adequately studied.

Methods

This single-centre, retrospective study analysed NSCLC patients with bone metastases who received first-line anti-PD1-therapy and concomitant denosumab treatment between March 2021 and June 2022. Clinical outcomes were described and bone lesion response was evaluated using a novel, exploratory quantitative method based on single photon emission computed tomography/computed tomography scans.

Results

Among 66 included patients, the median overall survival was 21.5 months (95% CI: 17.0-NR). The overall survival rate (95% CI) was 96.9% (92.9%–100.0%) at 6 months and 79.7% (70.4%–90.2%) at 12 months. The median progression-free survival was 7.7 months (95% CI: 6.2–12.8). The overall response rate was 36.4% (95% CI: 24.9%-49.1%), with 24 (36.4%) patients having partial response. An exploratory subgroup analysis showed that patients who received ≥ 6 doses of denosumab may have longer median overall survival compared to the < 6 doses subgroup (23.3 vs. 15.3 months, P = 0.023), though immortal time bias and confounding limit interpretation. Out of 33 bone lesions identified, 28 had decreased uptake values between consecutive bone scans (mean change in region-of-interest ratio: -32.7%±19.2%).

Conclusion

This study described real-world clinical NSCLC patients with bone metastases receiving concomitant anti-PD-1 therapy and denosumab. The findings should be interpreted as exploratory and hypothesis-generating given the retrospective, single-arm design. The novel, quantitative assessment method may provide an exploratory approach to monitoring changes in bone lesions, and further validation in larger, prospective cohorts is required.